#NASDAQ #Oncolytics Biotech #pelareorep

Oncolytics Biotech® Reinstates Compliance with Nasdaq

On July 22, 2025, Oncolytics Biotech® Inc. (traded under Nasdaq: ONCY and TSX: ONC), a front-runner in developing immunotherapy for cancer, received a Compliance Notice from The Nasdaq Stock Market. This letter confirmed that the company has met the minimum bid price requirement stipulated under Listing Rule 5550(a)(2). As a result, Oncolytics' common shares will continue to be listed and traded on the Nasdaq Capital Market, maintaining its ticker symbol "ONCY."

This recent compliance comes after a previous notification from Nasdaq dated February 13, 2025, in which Oncolytics was informed that their stock had fallen below the required minimum bid price of $1.00 for a stretch of 30 consecutive business days. However, thanks to a robust recovery, the company managed to elevate its closing bid price to $1.00 and above for 10 consecutive days, from July 8 to July 21, 2025, effectively addressing the issue and resulting in the closure of the matter.

Company Overview

Oncolytics Biotech is primarily focused on developing pelareorep, a revolutionary immunotherapeutic agent administered via intravenous route. Clinical trials have shown promising outcomes in various cancer types. Notably, in randomized Phase 2 studies involving metastatic breast cancer and in Phase 1 and 2 studies for pancreatic cancer, pelareorep showcased its potential to elicit strong anti-cancer immune responses. This includes transforming